Aliases & Classifications for Common Wart

Summaries for Common Wart

Disease Ontology : 12 A viral infectious disease that results_in infection located in skin, has material basis in human papillomavirus (types 2 and 4). This infection has symptom raised wart with roughened surface, most common on hands, but can grow anywhere on the body.

MalaCards based summary : Common Wart is related to syphilis and gonococcal synovitis, and has symptoms including raised wart An important gene associated with Common Wart is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Miconazole and Salicylic acid have been mentioned in the context of this disorder. Affiliated tissues include skin and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Related Diseases for Common Wart

Graphical network of the top 20 diseases related to Common Wart:



Diseases related to Common Wart

Symptoms & Phenotypes for Common Wart

Symptoms:

12
  • raised wart

GenomeRNAi Phenotypes related to Common Wart according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.8 CLEC7A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.8 CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.8 NFIC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.8 CLEC7A
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.8 NFIC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.8 CLEC7A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.8 NFIC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.8 NFIC
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.8 CLEC7A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.8 CLEC7A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.8 CLEC7A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.8 NFIC CD4 CLEC7A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.8 CLEC7A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.8 CLEC7A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.8 CLEC7A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.8 CLEC7A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.8 CD4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.8 CLEC7A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.8 CLEC7A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.8 CLEC7A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.8 CLEC7A
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.8 CLEC7A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.8 CD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.8 NFIC
25 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.8 CD4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.8 CLEC7A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.8 CLEC7A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.8 CLEC7A

MGI Mouse Phenotypes related to Common Wart:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 CD4 CD40 CD80 CLEC4E CLEC6A CLEC7A
2 immune system MP:0005387 9.23 CLEC4E CLEC6A CLEC7A LGALS3 TET2 CD4

Drugs & Therapeutics for Common Wart

Drugs for Common Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
2
Salicylic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3 69-72-7 338
3
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
4
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
5
Fluorouracil Approved Phase 4 51-21-8 3385
6
Pyruvate Approved, Nutraceutical Phase 4,Phase 2,Phase 3
7 Analgesics Phase 4,Phase 2,Phase 3
8 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
9 Antifungal Agents Phase 4,Phase 2,Phase 3
10 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
13 Antirheumatic Agents Phase 4,Phase 2,Phase 3
14 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3
15 Dermatologic Agents Phase 4,Phase 2,Phase 3
16 Keratolytic Agents Phase 4,Phase 2,Phase 3
17 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
18 Salicylates Phase 4,Phase 2,Phase 3
19 Liver Extracts Phase 4,Phase 3
20 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
23 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
24 interferons Phase 4,Phase 3,Phase 2,Phase 1
25 Antibodies Phase 4,Phase 1
26 Immunoglobulins Phase 4,Phase 1
27 Micronutrients Phase 4,Phase 2,Phase 3
28 Trace Elements Phase 4,Phase 2,Phase 3
29 Antimetabolites Phase 4,Phase 1,Phase 2
30 Antimetabolites, Antineoplastic Phase 4,Phase 1,Phase 2
31
Catechin Nutraceutical Phase 4,Phase 1 154-23-4 9064
32
Epicatechin Nutraceutical Phase 4,Phase 1 490-46-0 72276
33 Tea Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
34
Ethanol Approved Phase 2, Phase 3 64-17-5 702
35
Petrolatum Approved Phase 2, Phase 3 8009-03-8
36
Aminolevulinic acid Approved Phase 3 106-60-5 137
37
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
38
Pancrelipase Approved Phase 3 53608-75-6
39
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
40
Furosemide Approved, Vet_approved Phase 3,Phase 2 54-31-9 3440
41
Lenograstim Approved Phase 3 135968-09-1
42 Zinc sulfate Approved Phase 3 7733-02-0
43 tannic acid Approved, Nutraceutical Phase 3
44 Pharmaceutical Solutions Phase 2, Phase 3, Phase 1
45 Alkylating Agents Phase 3
46 Antineoplastic Agents, Alkylating Phase 3
47 Methyl 5-aminolevulinate Phase 3
48 Photosensitizing Agents Phase 3
49 pancreatin Phase 3
50 diuretics Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 177)
id Name Status NCT ID Phase
1 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Unknown status NCT01712295 Phase 4
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Completed NCT00761371 Phase 4
4 Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy Completed NCT01609530 Phase 4
5 Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Completed NCT00189293 Phase 4
6 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4
7 Alternate Dosing Schedules Study for HPV Vaccine (ADS) Completed NCT02280642 Phase 4
8 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
9 Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study Recruiting NCT02622568 Phase 4
10 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Recruiting NCT02087384 Phase 4
11 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4
12 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Not yet recruiting NCT03180034 Phase 4
13 A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4
14 Comparison of Five Treatments in Patients With Plantar Warts Terminated NCT01059110 Phase 4
15 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3
16 Topical 5-ALA Photodynamic Therapy for the Treatment of Verruca Vulgaris Unknown status NCT00155584 Phase 3
17 Efficacy of Laser Versus Cryotherapy in the Treatment of Warts Unknown status NCT01808443 Phase 3
18 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
19 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3
20 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3
21 Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01783353 Phase 2, Phase 3
22 Low Dose Cyclophosphamide Treats Genital Warts Completed NCT00999986 Phase 3
23 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
24 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
25 An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
26 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3
27 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
28 Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) Completed NCT00517309 Phase 3
29 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
30 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
31 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed NCT00092495 Phase 3
32 Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Completed NCT00092482 Phase 3
33 Evaluation of Long Term Immunity Following HPV Vaccination Completed NCT02276521 Phase 2, Phase 3
34 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
35 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Completed NCT00677677 Phase 3
36 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
37 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
38 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3
39 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3
40 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
41 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
42 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
43 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
44 A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 12 Years of Age or Older With Cutaneous Common Warts Recruiting NCT02971891 Phase 3
45 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Recruiting NCT02231879 Phase 3
46 A Trial of X4P-001 in Patients With WHIM Syndrome Recruiting NCT03005327 Phase 2, Phase 3
47 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3
48 Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts Not yet recruiting NCT03158168 Phase 3
49 Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients Not yet recruiting NCT03153566 Phase 3
50 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts Not yet recruiting NCT02750202 Phase 3

Search NIH Clinical Center for Common Wart

Genetic Tests for Common Wart

Anatomical Context for Common Wart

MalaCards organs/tissues related to Common Wart:

39
Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Common Wart:

18
Skin

Publications for Common Wart

Articles related to Common Wart:

(show all 28)
id Title Authors Year
1
Hyperkeratotic acral melanoma mimicking a common wart. ( 25973355 )
2015
2
Keratotic horn on left fifth fingertip: congenital ectopic nail misdiagnosed as a common wart. ( 22277059 )
2013
3
Measles, mumps, and rubella vaccine: a new option to treat common warts? ( 23786798 )
2013
4
Comparative study of topical 80% trichloroacetic acid with 35% trichloroacetic acid in the treatment of the common wart. ( 23135096 )
2012
5
Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. ( 20202055 )
2010
6
Treatment options for the common wart. ( 18210913 )
2007
7
Plantar verrucous carcinoma (epithelloma cuniculatum): rare form of the common wart. ( 17214114 )
2006
8
Human leukocyte antigen class II alleles and natural history of HPV 2/27/57-induced common warts. ( 15257408 )
2004
9
Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts. ( 15452412 )
2004
10
Is duct tape occlusion therapy as effective as cryotherapy for the treatment of the common wart? ( 12361441 )
2002
11
The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). ( 12361440 )
2002
12
Human papillomavirus associated Bowen's disease of the foot: unique clinical features mimicking a common wart. ( 11525958 )
2001
13
Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. ( 11069514 )
2000
14
Simultaneously detected aberrant p53 tumor suppressor protein and HPV-DNA localize mostly in separate keratinocytes in anogenital and common warts. ( 8734914 )
1996
15
Efficacious treatment of the common wart (verruca vulgaris). ( 1462533 )
1992
16
[Systemic treatment of common warts with beta-interferon]. ( 1917463 )
1991
17
Characterization of two HPV-3 related papillomaviruses from common warts that are distinct clinically from flat warts or epidermodysplasia verruciformis. ( 6302170 )
1983
18
An unusual transformation of a common wart in a child. ( 6269499 )
1981
19
Stump the experts. A common wart. ( 7338585 )
1981
20
Transformation of the common wart into squamous cell carcinoma in a patient with primary lymphedema. ( 7248909 )
1981
21
The common wart: intralesional treatment with bleomycin sulfate. ( 6159138 )
1980
22
Treatment of the common wart by induced allergic inflammation. ( 7389963 )
1980
23
Treatment of the common wart with a virus vaccine. ( 14477428 )
1962
24
Aralen and plaquenil in treatment of the common wart. ( 13726985 )
1961
25
Morphological characterization of the virus of the human common wart (verruca vulgaris). ( 13785470 )
1961
26
Common wart conjunctivitis. ( 13196997 )
1954
27
Treatment of the common wart by x-ray therapy. ( 13164671 )
1954
28
Contact x-ray therapy of the common wart. ( 14914174 )
1952

Variations for Common Wart

Expression for Common Wart

Search GEO for disease gene expression data for Common Wart.

Pathways for Common Wart

Pathways related to Common Wart according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 CD209 CD4 CD40 CD80 CLEC4E CLEC6A
2
Show member pathways
12.49 CD209 CLEC4E CLEC6A CLEC7A CXCL8
3
Show member pathways
12.45 CD4 CD40 CD80 CXCL8
4
Show member pathways
12.05 CD4 CD40 CD80
5
Show member pathways
11.87 CD209 CLEC4E CLEC6A CLEC7A
6 11.86 CD209 CLEC4E CLEC7A
7 11.71 CD4 CD40 CD80
8 11.57 CD209 CD4 CD80
9 11.23 CD80 CXCL8
10 11.21 CD40 CXCL8
11 11.18 CD4 CD80
12 11.05 CD4 CD40
13 10.98 CD40 CD80
14 10.52 CD4 CD40 CD80

GO Terms for Common Wart

Cellular components related to Common Wart according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.26 CD209 CD4 CD40 CD80
2 external side of plasma membrane GO:0009897 8.92 CD209 CD4 CD40 CD80

Biological processes related to Common Wart according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 CD4 CD40 CLEC4E CXCL8
2 adaptive immune response GO:0002250 9.69 CD209 CD4 CLEC6A
3 innate immune response GO:0045087 9.65 CD209 CLEC4E CLEC6A CLEC7A LGALS3
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.63 CD4 CD40 CLEC6A
5 cellular response to lipopolysaccharide GO:0071222 9.58 CD40 CD80 CXCL8
6 positive regulation of cytokine secretion GO:0050715 9.49 CLEC4E CLEC6A
7 defense response to protozoan GO:0042832 9.43 CD40 CLEC7A
8 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.37 CD4 CD80
9 T cell activation GO:0042110 9.33 CD4 CD80 CLEC7A
10 regulation of T cell proliferation GO:0042129 9.32 CD209 LGALS3
11 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.26 CD209 CLEC4E CLEC6A CLEC7A
12 immune system process GO:0002376 9.17 CD209 CD4 CD40 CLEC4E CLEC6A CLEC7A

Molecular functions related to Common Wart according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor activity GO:0004872 9.43 CD4 CD40 CLEC4E
2 coreceptor activity GO:0015026 9.16 CD4 CD80
3 virus receptor activity GO:0001618 9.13 CD209 CD4 CD80
4 carbohydrate binding GO:0030246 9.02 CD209 CLEC4E CLEC6A CLEC7A LGALS3

Sources for Common Wart

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....